BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 36519233)

  • 41. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sepsis-Related Outcomes of Patients with Philadelphia-Negative Myeloproliferative Neoplasms.
    Gonzalez-Mosquera LF; Moscoso B; Tobar P; Cardenas-Maldonado D; Podrumar AI; Mesa R; Cuenca JA
    Cancer Invest; 2023 May; 41(5):423-431. PubMed ID: 36883674
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients.
    Geyer HL; Scherber RM; Dueck AC; Kiladjian JJ; Xiao Z; Slot S; Zweegman S; Sackmann F; Fuentes AK; Hernández-Maraver D; Döhner K; Harrison CN; Radia D; Muxi P; Besses C; Cervantes F; Johansson PL; Andreasson B; Rambaldi A; Barbui T; Vannucchi AM; Passamonti F; Samuelsson J; Birgegard G; Mesa RA
    Blood; 2014 Jun; 123(24):3803-10. PubMed ID: 24553173
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Automated diagnostic support system with deep learning algorithms for distinction of Philadelphia chromosome-negative myeloproliferative neoplasms using peripheral blood specimen.
    Kimura K; Ai T; Horiuchi Y; Matsuzaki A; Nishibe K; Marutani S; Saito K; Kaniyu K; Takehara I; Uchihashi K; Ohsaka A; Tabe Y
    Sci Rep; 2021 Feb; 11(1):3367. PubMed ID: 33564094
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.
    Rontauroli S; Castellano S; Guglielmelli P; Zini R; Bianchi E; Genovese E; Carretta C; Parenti S; Fantini S; Mallia S; Tavernari L; Sartini S; Mirabile M; Mannarelli C; Gesullo F; Pacilli A; Pietra D; Rumi E; Salmoiraghi S; Mora B; Villani L; Grilli A; Rosti V; Barosi G; Passamonti F; Rambaldi A; Malcovati L; Cazzola M; Bicciato S; Tagliafico E; Vannucchi AM; Manfredini R
    Blood Adv; 2021 Mar; 5(5):1452-1462. PubMed ID: 33666652
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Next-generation sequencing redefines the diagnosis of triple-negative myeloproliferative neoplasms.
    Wu S; Luo P; Yu Y; Xiong B; Wang Y; Zuo X
    Ann Hematol; 2022 Mar; 101(3):705-708. PubMed ID: 34518917
    [No Abstract]   [Full Text] [Related]  

  • 47. [Utility of bone marrow biopsy in the diagnosis of myeloproliferative neoplasm].
    Tovar-Bobadilla JL; Ortiz-Hidalgo C
    Gac Med Mex; 2016; 152(3):407-18. PubMed ID: 27335198
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Assessing disease burden in patients with classic MPNs.
    Geyer H; Mesa RA
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):107-19. PubMed ID: 25189722
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostication in MF: from CBC to cytogenetics to molecular markers.
    Zhou A; Oh ST
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):155-64. PubMed ID: 25189726
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Disease-Specific Derangement of Circulating Endocannabinoids and
    Forte D; Fanelli F; Mezzullo M; Barone M; Corradi G; Auteri G; Bartoletti D; Martello M; Ottaviani E; Terragna C; Curti A; Pagotto U; Palandri F; Cavo M; Catani L
    Int J Mol Sci; 2020 May; 21(9):. PubMed ID: 32403407
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphia-negative myeloproliferative neoplasm.
    Song IC; Yeon SH; Lee MW; Ryu H; Lee HJ; Yun HJ; Kim SY; Jo DY
    Korean J Intern Med; 2021 Sep; 36(5):1190-1203. PubMed ID: 34289585
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
    Puglianini OC; Peker D; Zhang L; Papadantonakis N
    Lab Med; 2023 Jan; 54(1):13-22. PubMed ID: 35960786
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
    Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
    Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunoblotting-assisted assessment of JAK/STAT and PI3K/Akt/mTOR signaling in myeloproliferative neoplasms CD34+ stem cells.
    Calabresi L; Balliu M; Bartalucci N
    Methods Cell Biol; 2022; 171():81-109. PubMed ID: 35953207
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Top advances of the year: Myeloproliferative neoplasms.
    Bhave RR; Mesa R; Grunwald MR
    Cancer; 2023 Dec; 129(23):3685-3691. PubMed ID: 37768996
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Outcome Disparities in Caucasian and Non-Caucasian Patients With Myeloproliferative Neoplasms.
    Khan I; Shergill A; Saraf SL; Chen YF; Patel PR; Quigley JG; Peace D; Gordeuk VR; Hoffman R; Rondelli D
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):350-7. PubMed ID: 27052852
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.
    Gerds AT; Gotlib J; Ali H; Bose P; Dunbar A; Elshoury A; George TI; Gundabolu K; Hexner E; Hobbs GS; Jain T; Jamieson C; Kaesberg PR; Kuykendall AT; Madanat Y; McMahon B; Mohan SR; Nadiminti KV; Oh S; Pardanani A; Podoltsev N; Rein L; Salit R; Stein BL; Talpaz M; Vachhani P; Wadleigh M; Wall S; Ward DC; Bergman MA; Hochstetler C
    J Natl Compr Canc Netw; 2022 Sep; 20(9):1033-1062. PubMed ID: 36075392
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genotype-phenotype interactions in the myeloproliferative neoplasms.
    Godfrey AL; Green AR
    Hematol Oncol Clin North Am; 2012 Oct; 26(5):993-1015. PubMed ID: 23009934
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview.
    Tefferi A
    Mayo Clin Proc; 1998 Dec; 73(12):1177-84. PubMed ID: 9868417
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Circulating YKL-40 in Philadelphia-negative myeloproliferative neoplasms.
    Krečak I; Gverić-Krečak V; Lapić I; Rončević P; Gulin J; Fumić K; Krečak F; Holik H; Duraković N
    Acta Clin Belg; 2021 Feb; 76(1):32-39. PubMed ID: 31455178
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.